Allergies
Clinical trials for Allergies explained in plain language.
Never miss a new study
Get alerted when new Allergies trials appear
Sign up with your email to follow new studies for Allergies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could an allergy drug tame COPD Flare-Ups?
Disease control Recruiting nowThis study tests if omalizumab (Xolair), an allergy drug, can reduce serious flare-ups in people with COPD who also have allergies. About 334 participants will receive injections of the drug or a placebo for 12 months. The goal is to see if the drug lowers the number of COPD exac…
Matched conditions: ALLERGIES
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Apple a day keeps the allergy away? new trial tests raw apple therapy
Disease control Recruiting nowThis study tests whether eating small, increasing amounts of raw apple can reduce mouth allergy symptoms in people who are allergic to both birch pollen and apples. 110 participants will eat either real apple or a placebo over 9 months. The goal is to see if they can tolerate a l…
Matched conditions: ALLERGIES
Phase 3 • Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New liquid diet trial aims to help patients with severe bowel disorders
Disease control Recruiting nowThis study is testing an upgraded amino acid-based nutritional supplement for 30 children and adults who have severe gut problems like inflammatory bowel disease, short bowel syndrome, or severe allergies. Participants will use the supplement as part of their diet for 28 days. Re…
Matched conditions: ALLERGIES
Sponsor: Nutricia UK Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a higher dose of xolair beat food allergies?
Disease control Recruiting nowThis study tests if higher doses of omalizumab (Xolair) can help people with food allergies tolerate more of their trigger foods. Thirty participants with allergies to peanut, cashew, walnut, egg, or milk will receive either 5 mg/kg or 15 mg/kg of omalizumab for 16 weeks. The goa…
Matched conditions: ALLERGIES
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC